REIMBURSEMENT DECISION LANDSCAPE FOR ORPHAN DRUGS ACROSS SIX HTA AGENCIES

被引：0

作者：

Mittal, L. K. ^{[1
]}

Banerjee, P. ^{[2
]}

Kapoor, A. ^{[2
]}

Ligade, V. S. ^{[1
]}

机构：

[1] Manipal Univ, Manipal, Karnataka, India

[2] Optum Global Solut, Noida, India

来源：

VALUE IN HEALTH | 2016年 / 19卷 / 03期

关键词：

D O I：

10.1016/j.jval.2016.03.1032

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

PSY93

引用

页码：A257 / A257

页数：1

共 50 条

[41] INTERNATIONAL COMPARISON OF HTA DECISIONS FOR ORPHAN AND NON-ORPHAN ONCOLOGY DRUGS
Achour, L.
Hanna, E.
Borissov, B. N.
Ma, F.
Toumi, M.
[J]. VALUE IN HEALTH, 2018, 21 : S23 - S23
[42] GAUGING THE ROLE OF HTA IN REIMBURSEMENT DECISION-MAKING ACROSS SEVEN MARKETS IN ASIA-PACIFIC
Dummett, H.
Shankland, B. D. T.
[J]. VALUE IN HEALTH, 2010, 13 (07) : A516 - A516
[43] THE PATIENT PERSPECTIVE IN HEALTH TECHNOLOGY ASSESSMENT REIMBURSEMENT DECISIONS FOR ORPHAN DRUGS ACROSS DIFFERENT COUNTRIES
Nicholson, L.
Langham, S.
Adkins, E.
[J]. VALUE IN HEALTH, 2019, 22 : S860 - S860
[44] BRIDGING HTA AGENCIES ACROSS EUROPE: A SYSTEMATIC APPROACH TO CATEGORIZE EVOLVING AGENCIES
Nagy, L.
Kamal-Bahl, S.
Brandtmueller, A.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A268 - A268
[45] INTER-COUNTRY VARIABILITY IN COVERAGE DECISIONS FOR ORPHAN DRUGS: CRITERIA DRIVING HTA RECOMMENDATIONS IN SIX COUNTRIES
Nicod, E.
Kanavos, P.
[J]. VALUE IN HEALTH, 2013, 16 (03) : A3 - A3
[46] HOW CAN PHARMA INDUSTRY PREPARE ITSELF FOR THE CHANGING PRICING AND REIMBURSEMENT LANDSCAPE OF ORPHAN DRUGS IN EU?
Mukku, S.
Pang, F.
Mcconkey, D.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A357 - A357
[47] ANALYSIS OF FACTORS INFLUENCING DECISION MAKING ON TYPE 2 DIABETES DRUGS IN 5 HTA-AGENCIES
Adalsteinsson, E.
Jensen, R. C. O.
Mondher, T.
Hemels, M.
[J]. VALUE IN HEALTH, 2009, 12 (07) : A415 - A415
[48] DOES THE PRESENCE OF AN ORPHAN DRUG POLCY AFFECT HTA RECOMMENDATIONS FOR ONCOLOGIC ORPHAN DRUGS?
Riemer, J.
Hancock-Howard, R.
Gauthier, A.
[J]. VALUE IN HEALTH, 2017, 20 (09) : A570 - A570
[49] Reimbursement of orphan drugs: the Pompe and Fabry case in the Netherlands
Rinke van den Brink
[J]. Orphanet Journal of Rare Diseases, 9 (Suppl 1)
[50] Pricing and reimbursement of orphan drugs: the need for more transparency
Steven Simoens
[J]. Orphanet Journal of Rare Diseases, 6

← 1 2 3 4 5 →